Unknown

Dataset Information

0

Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial.


ABSTRACT:

Background

Immunotherapy with peptide hydrolysates from Lolium perenne (LPP) is an alternative treatment for seasonal allergic rhinitis with or without asthma. The aim of this study was to assess the clinical efficacy and safety of a cumulative dose of 170 ?g LPP administered subcutaneously over 3 weeks.

Methods

In a randomized, double-blind, placebo-controlled trial, 554 adults with grass pollen rhinoconjunctivitis were randomized (1:2 ratio) to receive 8 subcutaneous injections of placebo or 170 ?g LPP administered in increasing doses in 4 visits over 3 weeks. The primary outcome was the combined symptom and medication score (CSMS) measured over the peak pollen season. Reactivity to conjunctival provocation test (CPT) and quality of life (QOL) was assessed as secondary endpoints.

Results

The mean reduction in CSMS in the LPP vs placebo group was -15.5% (P = .041) during the peak period and -17.9% (P = .029) over the entire pollen season. LPP-treated group had a reduced reactivity to CPT (P < .001) and, during the pollen season, a lower rhinoconjunctivitis QOL global score (P = .005) compared with placebo group. Mostly mild and WAO grade 1 early systemic reaction (ESR) were observed ?30 minutes in 10.5% of LPP-treated patients, whereas 3 patients with a medical history of asthma (<1%) experienced a serious ESR that resolved with rescue medication.

Conclusion

Lolium perenne pollen peptides administered over 3 weeks before the grass pollen season significantly reduced seasonal symptoms and was generally safe and well-tolerated.

SUBMITTER: Mosges R 

PROVIDER: S-EPMC6175232 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: A randomized, multicenter, double-blind, placebo-controlled trial.

Mösges R R   Bachert C C   Panzner P P   Calderon M A MA   Haazen L L   Pirotton S S   Wathelet N N   Durham S R SR   Bonny M-A MA   Legon T T   von Frenckell R R   Pfaar O O   Shamji M H MH  

Allergy 20180621 9


<h4>Background</h4>Immunotherapy with peptide hydrolysates from Lolium perenne (LPP) is an alternative treatment for seasonal allergic rhinitis with or without asthma. The aim of this study was to assess the clinical efficacy and safety of a cumulative dose of 170 μg LPP administered subcutaneously over 3 weeks.<h4>Methods</h4>In a randomized, double-blind, placebo-controlled trial, 554 adults with grass pollen rhinoconjunctivitis were randomized (1:2 ratio) to receive 8 subcutaneous injections  ...[more]

Similar Datasets

| S-EPMC4101870 | biostudies-other
| S-EPMC4094440 | biostudies-literature
| S-EPMC4682243 | biostudies-literature
| S-EPMC5547534 | biostudies-literature
| S-EPMC4074663 | biostudies-literature
| S-EPMC5763416 | biostudies-literature
| S-EPMC5994829 | biostudies-literature
| S-EPMC4746770 | biostudies-other
| S-EPMC5539638 | biostudies-other
| S-EPMC3711679 | biostudies-literature